Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Angel L. Montejo
 + 1581 word(s) 1581 2021-01-21 05:05:06 |
2 format correct
Karina Chen
 Meta information modification 1581 2021-04-29 07:15:38 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Montejo, A.L. Treatment Emergent Sexual Dysfunction. Encyclopedia. Available online: https://encyclopedia.pub/entry/9170 (accessed on 07 July 2024).
Montejo AL. Treatment Emergent Sexual Dysfunction. Encyclopedia. Available at: https://encyclopedia.pub/entry/9170. Accessed July 07, 2024.
Montejo, Angel L.. "Treatment Emergent Sexual Dysfunction" Encyclopedia, https://encyclopedia.pub/entry/9170 (accessed July 07, 2024).
Montejo, A.L. (2021, April 28). Treatment Emergent Sexual Dysfunction. In Encyclopedia. https://encyclopedia.pub/entry/9170
Montejo, Angel L.. "Treatment Emergent Sexual Dysfunction." Encyclopedia. Web. 28 April, 2021.
Treatment Emergent Sexual Dysfunction
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm10020308

Antipsychotic medication can be often associated with sexual dysfunction (SD). Given its inti-mate nature, treatment emergent sexual dysfunction (TESD) remains underestimated in clinical practice. SD may cause diverse clinical alterations, such as low libido, difficulties in ejacu-lation, difficulties reaching orgasm, erection and vaginal lubrication, as well as men-strual alterations or gynecomastia. These alterations are mostly reversible with treatment discontinuation, except for priapism, which can require surgical interven-tion in some cases.

antipsychotic sexual dysfunction

1. Primary Prevention: Using APS with a Low Incidence of TESD

While many patients may not be on monotherapy and SD may emerge from a combination of drugs, prevention allows us to optimize the risk for SD when treating an antipsychotic-naïve patient. Although keeping first rank psychotic symptoms under control should be a priority, clinicians should always be wary of the potential for TESD of each drug at this point (Table 2). Overall, risperidone  and other classical APS [1][2][3][4][5][6] have a higher incidence of TESD when compared with other atypical neuroleptics such as clozapine [6][7][8], olanzapine [9], quetiapine [10][11][12][13], or aripiprazole [87–89]. When analyzing TESD by each sexual dimension comparing different APS, this becomes even more obvious, given how SD rates are so different for each antipsychotic [14].

Table 2. Mechanisms of action causing SD for each antipsychotic.

Antipsychotic

Mechanism of Action Causing SD

Endocrinological Changes

Dose at Which SD May Be More Likely to Appear

Haloperidol and other typical antipsychotics.

Strong D2 antagonism and decrease of dopamine function.

Hyperprolactinemia and related changes (low testosterone, decreased estrogen levels, LH, and FSH)

Any

Risperidone, paliperidone

Strong D2 antagonism and decrease of dopamine function; weak 5HT2C antagonism

Hyperprolactinemia and related changes

Any

Amisulpride

Strong D2 antagonism and decrease of dopamine function

Hyperprolactinemia and related changes

Any

Clozapine

Weak D2 antagonism, mild 5HT2A antagonism, H1 and M1 antagonism

Mild hyperprolactinemia, indirect effects (sedation)

Variable

Ziprasidone

Strong 5HT2A antagonism and moderate D2 antagonism and 5HT2C antagonism

Transient hyperprolactinemia

Unknown

Olanzapine

Strong 5HT2A antagonism and moderate D2 and 5HT2C antagonism

Hyperprolactinemia at higher doses

> 15 mg/day

Quetiapine

Weak D2 antagonism, mild 5HT2A and 5HT2C antagonism

Hyperprolactinemia at higher doses

> 500 mg/day

LH, luteinizing hormone; FSH, follicle-stimulating hormone.

Risperidone has been associated with other problems in addition to regular sexual dysfunction, like retrograde ejaculation and urinary dysfunctions [15][16][17][18][19]; anejaculation [20][21]; and, on rare occasions, hypersexuality [22][23]. Part of this SD could be related to high levels of blood prolactin [24], resulting in complex hormone regulations that decrease testosterone [25]. Some studies question prolactin levels as the sole mechanism of SD in risperidone [26], and it is likely that a blockade of 5HT2A and 5HT2C receptors at the prefrontal cortex may be responsible too [27][28]. Nonetheless, hyperprolactinemia also causes a variety of adverse effects and pathologies that go beyond sexual dysfunction, especially in the long-term [29].

Paliperidone, a metabolite of risperidone, has also been linked to hyperprolactinemia [30] and sexual dysfunction [31][32], with similar mechanisms involved. Therefore, hyperprolactinemic APS such as risperidone, paliperidone, amisulpride, and classical antipsychotics are not an appropriate first option if we wish to keep sexual function preserved in psychotic patients [33]. In turn, the other atypical antipsychotics fare slightly better in comparison[3].

Clozapine’s weaker blockade of D2 dopaminergic receptors in the mesostriatum is supposed to have a lesser incidence of orgasm dysfunction and erectile dysfunction when compared with typical neuroleptics [34][35], although not by a wide margin [36]. A case of hypersexual behavior with clozapine has been reported [37], although it is not a common adverse effect.

Ziprasidone, because of its mechanism of action (5-HT2 receptor antagonism facilitating dopamine release in the cortex), would theoretically improve orgasmic and erectile function, as suggested by some case reports concerning spontaneous ejaculation and priapism [38][39]. However, there is only one study researching its effect on sexual function to our knowledge. In a small (n = 15), 3-month observational study, patients who were antipsychotic-naïve commenced treatment with ziprasidone, preserving sexual functioning across all sexual dimensions, and even slightly improving the minor sexual dysfunction found in baseline [40]. Although promising, these results need further confirmation.

Olanzapine causes less extrapyramidal symptoms [9], less hyperprolactinemia [41], and less SD than haloperidol [42] and risperidone [43]. Orgasm, ejaculation, and arousal are usually less affected by olanzapine than by risperidone [44], as also suggested by some case reports of spontaneous ejaculation [45] and priapism [46]. However, some studies consider these differences to be relatively minor or nonexistent [47], especially when olanzapine doses reach 15–20 mg/day [48]. These results suggest that olanzapine causes a dose-dependent mild to moderate hyperprolactinemia.

Quetiapine, on the other hand, does not significantly increase prolactin levels [48]. There has been lower reported incidence of SD with quetiapine when compared with typical neuroleptics, and some atypical (risperidone and olanzapine) [49]. With one exception [5], most of the studies agree that, when dosing below 400 mg/day, sexual function is mostly preserved [11], but when dosing at around 500 mg/day and above, SD may appear with a severity in proportion to dosage [50], although usually less so than the previously mentioned antipsychotics [51]. Quetiapine has also been described as particularly helpful in preserving sexual arousal [5].

Aripiprazole, a partial dopamine receptors agonist, as well as its partial 5HT1A agonism and 5HT2A antagonism, has been correlated to no actual increase in prolactin levels [52]. In fact, when used in combination with another antipsychotic, it has been observed to lower already increased prolactin levels [53]. When dosing at around 15 mg/day, this results in no SD at all [54][55], or SD of mild intensity, usually being tolerable for the patient. One study concludes that aripiprazole causes less SD than risperidone, olanzapine, or quetiapine [56]. However, while aripiprazole remains the best option among the researched evidence when trying to prevent TESD [3], several cases of hypersexual behavior have been reported to be directly caused by this drug [57][58][59][60][61], which apparently can manifest at any dose, but seem to be more frequent when dosing above 20 mg/day [59]. Cariprazine, which is another dopamine partial agonist like aripiprazole that does not produce hyperprolactinemia [62][63], still has no published data regarding its effect on sexual function. Although it could be considered similar to aripiprazole, specific studies are needed.

2. Detection and Exploration of TESD

Psychotic patients are a very heterogeneous group in terms of clinical evolutions, treatment response, and sexual activity, so being mindful of this issue and its possible repercussions on adherence becomes difficult at times for both the clinician [64] and the patient. For example, uncompensated patients with acute symptomatology that require hospitalization do not share the same concern for their sexuality as fully stabilized chronic patients do ; clinicians treating the former may overlook this issue at first while attempting to treat psychotic symptomatology.

That is why, when SD shows up, it is crucial to examine how the patient accepts this adverse effect and how it influences their quality of life and overall functionality. The spontaneous communication rate of SD from patients is low [65], so medical staff should routinely check with the patients to detect if TESD exists by asking clear questions, such as “How has your sexual life been since you started taking the medication?” and “Have you noticed any change that worries you?” This issue should always be approached in a neutral manner, expressing concern about the patient’s wellbeing and informing them about the potential sexual side effects of APS medication [66]. Gathering a full sexual medical history is useful to thoroughly understand the onset of the first SD symptoms, SD severity, the impact of SD on the sexual lives of the patient and their partner, and the influence of SD on the patient’s quality of life [67]. This thorough evaluation would also help to determine whether SD is in fact a consequence of antipsychotic treatment or is caused by other factors such as comorbidities, substance abuse, or other prescribed medication [68].

To better quantify TESD and measure its degree of acceptance by the patient, several specific validated scales and structured questionnaires can be of use. As the rate of SD can vary depending on which scale is used [1], a combination of several of them would be best in order to best determine its existence and its intensity, especially when researching this issue [69].

A few suitable options for measuring TESD caused by antipsychotics are the following [70]: the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX, free download at http://sexualidadysaludmental.com/salsex.html)) [71][72]; the Changes in Sexual Functioning Questionnaire (CSFQ) [73]; the Antipsychotics and Sexual Functioning Questionnaire (ASFQ) [139]; the Arizona Sexual Experiences Scale (ASEX) [74][75][76]; the Nagoya Sexual Function Questionnaire (NSFQ) [77]; and the Antipsychotic Non-Neurological Side Effects Rating Scale for sexual dysfunction (ANNSERS) [78]. The PRSexDQ, ASFQ, and CSFQ cover all stages of sexual functioning, which makes them preferrable [70]. To further measure the severity of SD, the International Index of Erectile Function (IIEF) and the Sexual Encounter Profile (SEP) [79] are valid options for men, and the Sexual Interest and Desire Inventory-Female (SIDI-F) for women [80].

3. Intervention

Once TESD is identified, if it is poorly tolerated by the patient and risks compromising adherence, it may be possible to intervene depending on the particular clinical symptoms of each case. While sometimes, fully restoring previous sexual function is not achievable, partially alleviating the experienced symptoms can satisfy the patient’s expectations without jeopardizing the antipsychotic effect of their treatment. When compared with SD caused by antidepressants, the literature on intervention in TESD caused by APS is scarce, and frequently inconsistent [81], although some viable options emerge. Some possible strategies for treating TESD are the following: (1) waiting for spontaneous remission; (2) dose reduction; (3) switching to another APS; and (4) the addition of an antidote (coadjuvant drug). None of these methods is devoid of risks, such as a relapse, so a careful individualized approach is suggested so that patients can make an informed choice.

References

  1. Nebhinani, N.; Grover, S.; Avasthi, A. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: Rates vary with assessment questionnaire. Prim. Care Companion CNS Disord. 2012, 14, PCC.11m01199.
  2. Mahmoud, A.; Hayhurst, K.P.; Drake, R.J.; Lewis, S.W. Second generation antipsychotics improve sexual dysfunction in schizophrenia: A randomised controlled trial. Schizophr. Res. Treat. 2011, 2011, 596898.
  3. Baggaley, M. Sexual dysfunction in schizophrenia: Focus on recent evidence. Hum. Psychopharmacol. 2008, 23, 201–209.
  4. Dossenbach, M.; Erol, A.; el Mahfoud Kessaci, M.; Shaheen, M.O.; Sunbol, M.M.; Boland, J.; Hodge, A.; O’Halloran, R.A.; Bitter, I.; IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry 2004, 65, 312–321.
  5. Kelly, D.L.; Conley, R.R. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006, 31, 340–346.
  6. Mullen, B.; Brar, J.S.; Vagnucci, A.H.; Ganguli, R. Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. Schizophr. Res. 2001, 48, 155–158.
  7. Burke, M.A.; McEvoy, J.P.; Ritchie, J.C. A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biol. Psychiatry 1994, 35, 32–35.
  8. Wirshing, D.; Pierre, J.; Marder, S.; Saunders, C.; Wirshing, W. Sexual side effects of novel antipsychotic medications. Schizophr. Res. 2002, 56, 25–30.
  9. Tran, P.V.; Hamilton, S.H.; Kuntz, A.J.; Potvin, J.H.; Andersen, S.W.; Beasley, C.; Tollefson, G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997, 17, 407–418.
  10. Westheide, J.; Cvetanovska, G.; Albrecht, C.; Bliesener, N.; Cooper-Mahkorn, D.; Creutz, C.; Hornung, W.-P.; Klingmüller, D.; Lemke, M.R.; Maier, W.; et al. Prolactin, subjective well-being and sexual dysfunction: An open label observational study comparing quetiapine with risperidone. J. Sex. Med. 2008, 5, 2816–2826.
  11. Nakonezny, P.A.; Byerly, M.J.; Rush, A.J. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. J. Sex Marital Ther. 2007, 33, 203–216.
  12. Cheer, S.M.; Wagstaff, A.J. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 2004, 18, 173–199.
  13. Cutler, A.J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003, 28 (Suppl. 1), 69–82.
  14. Knegtering, H.; Bruggeman, R.; Castelein, S.; Wiersma, D. Antipsychotics and sexual functioning in persons with psychoses. Tijdschr. Psychiatr. 2007, 49, 733–742.
  15. Shanmugasundaram, N.; Nivedhya, J.; Karthik, M.S.; Ramanathan, S. Risperidone-induced retrograde ejaculation and lurasidone may be the alternative. Ind. Psychiatry J. 2019, 28, 152–154.
  16. Loh, C.; Leckband, S.G.; Meyer, J.M.; Turner, E. Risperidone-induced retrograde ejaculation: Case report and review of the literature. Int. Clin. Psychopharmacol. 2004, 19, 111–112.
  17. Holtmann, M.; Gerstner, S.; Schmidt, M.H. Risperidone-associated ejaculatory and urinary dysfunction in male adolescents. J. Child Adolesc. Psychopharmacol. 2003, 13, 107–109.
  18. Storch, D.D. Risperidone-induced retrograde ejaculation. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41, 365–366.
  19. Kaneda, Y. Risperidone-induced ejaculatory dysfunction: A case report. Eur. Psychiatry 2001, 16, 134–135.
  20. Compton, M.T. Risperidone-induced ejaculatory disturbances. Psychiatr. Serv. 2002, 53, 347.
  21. Raja, M. Risperidone-induced absence of ejaculation. Int. Clin. Psychopharmacol. 1999, 14, 317–319.
  22. Davidson, C.K.D.; Johnson, T.; Jansen, K. Risperidone-induced hypersexuality. Br. J. Psychiatry 2013, 203, 233.
  23. Lam, M.H.B.; Fong, S.Y.Y.; Wing, Y.-K. Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine. Psychiatry Clin. Neurosci. 2007, 61, 333.
  24. Shiwach, R.S.; Carmody, T.J. Prolactogenic effects of risperidone in male patients—A preliminary study. Acta Psychiatr. Scand. 1998, 98, 81–83.
  25. Liu-Seifert, H.; Kinon, B.J.; Tennant, C.J.; Sniadecki, J.; Volavka, J. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr. Dis. Treat. 2009, 5, 47–54.
  26. Spollen, J.J.; Wooten, R.G.; Cargile, C.; Bartztokis, G. Prolactin levels and erectile function in patients treated with risperidone. J. Clin. Psychopharmacol. 2004, 24, 161–166.
  27. Zhang, X.R.; Zhang, Z.J.; Jenkins, T.A.; Cheng, W.R.; Reynolds, G.P. The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat. J. Sex. Med. 2011, 8, 3345–3353.
  28. Drago, F.; Contarino, A.; Marino, R.; Anzallo, C.; Valerio, C.; Rampello, L.; Raffaele, R.; Scapagnini, U. Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacol. Res. 1997, 35, 17–25.
  29. Montejo, Á.L.; Arango, C.; Bernardo, M.; Carrasco, J.L.; Crespo-Facorro, B.; Cruz, J.J.; Del Pino, J.; Escudero, M.A.G.; Rizo, C.G.; González-Pinto, A.; et al. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Rev. Psiquiatr. Salud Ment. (Engl. Ed.) 2016, 9, 158–173.
  30. Bostwick, J.R.; Guthrie, S.K.; Ellingrod, V.L. Antipsychotic-Induced Hyperprolactinemia. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2009, 29, 64–73.
  31. Madan, R.; Langenfeld, R.J.; Ramaswamy, S. Paliperidone Palmitate-Induced Retrograde Ejaculation. Clin. Schizophr. Relat. Psychoses 2018, 12, 86–88.
  32. Potkin, S.G.; Loze, J.-Y.; Forray, C.; Baker, R.A.; Sapin, C.; Peters-Strickland, T.; Beillat, M.; Nylander, A.-G.; Hertel, P.; Andersen, H.S.; et al. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: Results from QUALIFY. Int. Clin. Psychopharmacol. 2017, 32, 147–154.
  33. De Hert, M.; Detraux, J.; Peuskens, J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: A critical literature review. Expert Opin. Drug Saf. 2014, 13, 605–624.
  34. Pfaus, J.G.; Phillips, A.G. Differential effects of dopamine receptor antagonists on the sexual behavior of male rats. Psychopharmacology 1989, 98, 363–368.
  35. Hummer, M.; Kemmler, G.; Kurz, M.; Kurzthaler, I.; Oberbauer, H.; Fleischhacker, W.W. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am. J. Psychiatry 1999, 156, 631–633.
  36. Aizenberg, D.; Modai, I.; Landa, A.; Gil-Ad, I.; Weizman, A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J. Clin. Psychiatry 2001, 62, 541–544.
  37. Thomson, S.R.; Patil, N.; Ommurugan, B.; Bhandary, R.K. A Case of Hyper Sexuality Probably Associated with Clozapine. Psychopharmacol. Bull. 2018, 48, 20–24.
  38. Boora, K.; Chiappone, K.; Dubovsky, S.; Xu, J. Ziprasidone-induced spontaneous orgasm. J. Psychopharmacol. 2010, 24, 947–948.
  39. Kaufman, K.R.; Stern, L.; Mohebati, A.; Olsavsky, A.; Hwang, J. Ziprasidone-induced priapism requiring surgical treatment. Eur. Psychiatry 2006, 21, 48–50.
  40. Montejo, A.L.; Rico-Villademoros, F.; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study. J. Clin. Psychopharmacol. 2008, 28, 568–570.
  41. Costa, A.M.N.; de Lima, M.S.; Faria, M.; Filho, S.R.; de Oliveira, I.R.; de Jesus Mari, J. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J. Psychopharmacol. 2007, 21, 165–170.
  42. Beasley, C.M.; Tollefson, G.D.; Tran, P.V. Safety of olanzapine. J. Clin. Psychiatry 1997, 58 (Suppl. 10), 13–17.
  43. Bitter, I.; Basson, B.R.; Dossenbach, M.R. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. Int. Clin. Psychopharmacol. 2005, 20, 19–21.
  44. Knegtering, H.; Boks, M.; Blijd, C.; Castelein, S.; van den Bosch, R.J.; Wiersma, D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J. Sex Marital Ther. 2006, 32, 315–326.
  45. Yektas, Ç.; Tufan, A.E. Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report. Clin. Neuropharmacol. 2016, 39, 157–158.
  46. Songer, D.A.; Barclay, J.C. Olanzapine-induced priapism. Am. J. Psychiatry 2001, 158, 2087–2088.
  47. Nagaraj, A.K.M.; Pai, N.B.; Rao, S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J. Psychiatry 2009, 51, 265–271.
  48. Byerly, M.J.; Nakonezny, P.A.; Bettcher, B.M.; Carmody, T.; Fisher, R.; Rush, A.J. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr. Res. 2006, 86, 244–250.
  49. Hanssens, L.; L’Italien, G.; Loze, J.-Y.; Marcus, R.N.; Pans, M.; Kerselaers, W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008, 8, 95.
  50. Atmaca, M.; Kuloglu, M.; Tezcan, E. A new atypical antipsychotic: Quetiapine-induced sexual dysfunctions. Int. J. Impot. Res. 2005, 17, 201–203.
  51. Byerly, M.J.; Lescouflair, E.; Weber, M.T.; Bugno, R.M.; Fisher, R.; Carmody, T.; Varghese, F.; Rush, A.J. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J. Sex Marital Ther. 2004, 30, 325–332.
  52. Kirino, E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: Comparison between aripiprazole and other atypical antipsychotics. Ann. Gen. Psychiatry 2017, 16, 43.
  53. Kozian, R. Hypersexuality Induced by Aripiprazole. Psychiatr. Prax. 2020, 47, 43–45. (In German)
  54. Shah, S.K. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ. Med. J. 2013, 11, 121–125.
  55. de Boer, M.K.; Wiersma, D.; Bous, J.; Sytema, S.; van der Moolen, A.E.G.M.; Wilffert, B.; Hamamura, T.; Knegtering, H. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J. Clin. Psychopharmacol. 2011, 31, 523–525.
  56. Hanssens, L.; L’Italien, G.; Loze, J.-Y.; Marcus, R.N.; Pans, M.; Kerselaers, W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008, 8, 95.
  57. Kozian, R. Hypersexuality Induced by Aripiprazole. Psychiatr. Prax. 2020, 47, 43–45. (In German)
  58. Bulbena-Cabré, A.; Bulbena, A. Aripiprazole-Induced Hypersexuality. Prim. Care Companion CNS Disord. 2016, 18.
  59. Vrignaud, L.; Aouille, J.; Mallaret, M.; Durrieu, G.; Jonville-Béra, A.-P. Hypersexuality associated with aripiprazole: A new case and review of the literature. Therapie 2014, 69, 525–527.
  60. Cheon, E.; Koo, B.-H.; Seo, S.S.; Lee, J.-Y. Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Investig. 2013, 10, 200–202.
  61. Schlachetzki, J.C.M.; Langosch, J.M. Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? J. Clin. Psychopharmacol. 2008, 28, 567–568.
  62. Kane, J.M.; Zukin, S.; Wang, Y.; Lu, K.; Ruth, A.; Nagy, K.; Laszlovszky, I.; Durgam, S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. J. Clin. Psychopharmacol. 2015, 35, 367–373.
  63. Nasrallah, H.A.; Earley, W.; Cutler, A.J.; Wang, Y.; Lu, K.; Laszlovszky, I.; Németh, G.; Durgam, S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis. BMC Psychiatry 2017, 17, 305.
  64. Monteleone, P.; Amore, M.; Cabassi, A.; Clerici, M.; Fagiolini, A.; Girardi, P.; Jannini, E.A.; Maina, G.; Rossi, A.; Vita, A.; et al. Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients with Schizophrenia. Implications for Clinical Practice. Front. Psychiatry 2019, 10, 842.
  65. Martín, J.C.; Acuña, M.J.; Labrador, J.; Blanco, M.; Casas, C. Sexual dysfunction factors in patients with schizophrenia treated with second generation antipsychotics: Not only prolactin. Actas Esp. Psiquiatr. 2018, 46, 217–225.
  66. Higgins, A.; Barker, P.; Begley, C.M. Neuroleptic medication and sexuality: The forgotten aspect of education and care. J. Psychiatr. Ment. Health Nurs. 2005, 12, 439–446.
  67. Basson, R.; Rees, P.; Wang, R.; Montejo, A.L.; Incrocci, L. Sexual function in chronic illness. J. Sex. Med. 2010, 7, 374–388.
  68. La Torre, A.; Conca, A.; Duffy, D.; Giupponi, G.; Pompili, M.; Grözinger, M. Sexual dysfunction related to psychotropic drugs: A critical review part II: Antipsychotics. Pharmacopsychiatry 2013, 46, 201–208.
  69. De Hert, M.; Detraux, J.; Peuskens, J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: A critical literature review. Expert Opin. Drug Saf. 2014, 13, 605–624.
  70. de Boer, M.K.; Castelein, S.; Wiersma, D.; Schoevers, R.A.; Knegtering, H. A systematic review of instruments to measure sexual functioning in patients using antipsychotics. J. Sex Res. 2014, 51, 383–389.
  71. Montejo, Á.L.; Rico-Villademoros, F. Psychometric Properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in Patients with Schizophrenia and Other Psychotic Disorders. J. Sex Marital Ther. 2008, 34, 227–239.
  72. Wang, Y.-X.; Zhang, P.; Xin, L.-M.; Chen, L.; Liu, Y.-H.; Su, Y.-A.; Si, T.-M. Chinese version of the Psychotropic-related Sexual Dysfunction Questionnaire (PRSexDQ -SALSEX): Validity and reliability for schizophrenic patients taking antipsychotics. Psychiatry Res. 2016, 246, 303–307.
  73. Clayton, A.H.; McGarvey, E.L.; Clavet, G.J. The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacol. Bull. 1997, 33, 731–745.
  74. McGahuey, C.A.; Gelenberg, A.J.; Laukes, C.A.; Moreno, F.A.; Delgado, P.L.; McKnight, K.M.; Manber, R. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J. Sex Marital Ther. 2000, 26, 25–40.
  75. Arizona Sexual Experiences Scale (ASEX). Available online: https://www.mirecc.va.gov/visn22/Arizona_Sexual_Experiences_Scale.pdf (accessed on 7 September 2020).
  76. Byerly, M.J.; Nakonezny, P.A.; Fisher, R.; Magouirk, B.; Rush, A.J. An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophr. Res. 2006, 81, 311–316.
  77. Kikuchi, T.; Iwamoto, K.; Sasada, K.; Aleksic, B.; Yoshida, K.; Ozaki, N. Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Hum. Psychopharmacol. Clin. Exp. 2011, 26, 300–306.
  78. Mahmoud, A.; Hayhurst, K.P.; Drake, R.J.; Lewis, S.W.; Barnes, T.R.E. The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement. Ther. Adv. Psychopharmacol. 2011, 1, 97–100.
  79. Hackett, G. The use of questionnaires to assess sexual function. Trends Urol. Men’s Health 2017, 8, 17–20.
  80. Clayton, A.H.; Segraves, R.T.; Leiblum, S.; Basson, R.; Pyke, R.; Cotton, D.; Lewis-D’Agostino, D.; Evans, K.R.; Sills, T.L.; Wunderlich, G.R. Reliability and validity of the Sexual Interest and Desire Inventory-Female (SIDI-F), a scale designed to measure severity of female hypoactive sexual desire disorder. J. Sex Marital Ther. 2006, 32, 115–135.
  81. Schmidt, H.M.; Hagen, M.; Kriston, L.; Soares-Weiser, K.; Maayan, N.; Berner, M.M. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst. Rev. 2012, 11, CD003546.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Angel L. Montejo
View Times: 1.2K
Revisions: 2 times (View History)
Update Date: 29 Apr 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback